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Abstract
Background: Isotope-coded affinity tag (ICAT) tandem mass spectrometry (MS) allows for qualitative
and quantitative analysis of paired protein samples. We sought to determine whether ICAT technology
could quantify and identify differential expression of tumor-specific proteins in nipple aspirate fluid (NAF)
from the tumor-bearing and contralateral disease-free breasts of patients with unilateral early-stage breast
cancer.
Methods: Paired NAF samples from 18 women with stage I or II unilateral invasive breast carcinoma and
4 healthy volunteers were analyzed using ICAT labeling, sodium dodecyl sulfate-polyacrylamide gel (SDS-
PAGE), liquid chromatography, and MS. Proteins were identified by sequence database analysis. Western
blot analysis of NAF from an independent sample set from 12 women (8 with early-stage breast cancer
and 4 healthy volunteers) was also performed.
Results: 353 peptides were identified from tandem mass spectra and matched to peptide sequences in
the National Center for Biotechnology Information database. Equal numbers of peptides were up- versus
down-regulated. Alpha2HS-glycoprotein [Heavy:Light (H:L) ratio 0.63] was underexpressed in NAF from
tumor-bearing breasts, while lipophilin B (H:L ratio 1.42), beta-globin (H:L ratio 1.98), hemopexin (H:L
ratio 1.73), and vitamin D-binding protein precursor (H:L ratio 1.82) were overexpressed. Western blot
analysis of pooled samples of NAF from healthy volunteers versus NAF from women with breast cancer
confirmed the overexpression of vitamin D-binding protein in tumor-bearing breasts.
Conclusion: ICAT tandem MS was able to identify and quantify differences in specific protein expression
between NAF samples from tumor-bearing and disease-free breasts. Proteomic screening techniques using
ICAT and NAF may be used to find markers for diagnosis of breast cancer.
Published: 16 March 2006
BMC Cancer2006, 6:68 doi:10.1186/1471-2407-6-68
Received: 13 October 2005
Accepted: 16 March 2006
This article is available from: http://www.biomedcentral.com/1471-2407/6/68
© 2006Pawlik et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Cancer 2006, 6:68 http://www.biomedcentral.com/1471-2407/6/68
Page 2 of 10
(page number not for citation purposes)
Background
Despite the widespread adoption of screening mammog-
raphy, many breast cancers still escape detection at an
early stage [1,2]. Identifying relevant biologic markers
could improve our ability to diagnose early-stage breast
cancer [3-7]. Compared with DNA analysis (genomics)
and RNA analysis (expression profiling), the examination
of protein expression (proteomics) may be more relevant
to tumor physiology as protein stability and activity are
largely what determine cellular phenotype and function
[8]. Recent developments in proteomics have enabled
high-throughput analysis of thousands of proteins, mak-
ing possible the identification of new biologic markers [9-
11].
One of the most useful techniques that has emerged for
the detection of proteins and protein-derived peptides is
mass spectrometry (MS) [12-14]. Using surface-enhanced
laser desorption ionization time-of-flight (SELDI-TOF)
MS, we previously found differences in the phenotypic
proteomic profiles of nipple aspirate fluid (NAF) samples
from patients with early-stage breast cancer versus healthy
female volunteers [15]. However, although MS is power-
ful and allows, in principle, for the detection of many cop-
urifying proteins in a fraction, it remains difficult with MS
to distinguish specific from nonspecific interactions and
to detect quantitative changes in protein complex abun-
dance and composition without direct visualization of the
proteins in gels [16-18]. This is mainly because profiling
experiments such as SELDI in which MS-1 only is per-
formed, and not MS/MS, is not an inherently quantitative
technique [16,19-22] and does not allow for the specific
identification of individual peptides.
The development of methods and instrumentation for
automated, data-dependent electrospray ionization MS in
conjunction with microcapillary liquid chromatography
and database searching has significantly increased the sen-
sitivity and speed of large-scale protein identification
directly from mixtures [19,23,24]. Recently developed iso-
tope-coded affinity tag (ICAT) technology has greatly
expanded the range of proteins that can be analyzed,
quantified, and identified using these techniques
[19,25,26]. Unlike two-dimensional polyacrylamide gel
electrophoresis (PAGE) and SELDI-TOF MS, which com-
paratively profile the naturally occurring forms of pep-
tides and proteins, ICAT analysis profiles the relative
amounts of cysteine-containing peptides derived from
tryptic digests of protein extracts [9]. The isotope tags
[Cys-(na) light and Cys-(9 13C) heavy] covalently bind to
cysteine moieties of amino acids within proteins
[9,26,27]. ICAT has a large dynamic range, and the two
isotope labels act as mutual internal standards for quanti-
tation [28]. The mass difference between the proteins
labeled with the light and heavy tags allows for the sepa-
ration and comparison of peptides from each sample set
[19,26]. The small fraction of proteins lacking cysteine is
transparent to analysis, and only relative changes in pro-
tein abundance are interrogated [28]. After the peptide
mixture is separated using a reverse-phase liquid chroma-
tography electrospray ionization mass spectrometer, the
peptides are identified by sequence database analysis [16].
In this manner, ICAT proteomic analysis allows for not
only identification but also quantification of differentially
expressed proteins.
The purpose of the current study was to analyze NAF from
women with early stage breast cancer using quantitative
proteomic ICATs and tandem MS (MS/MS). In this paper,
we show that ICAT tandem MS is able both to identify and
quantify differences in specific protein expression
between NAF samples from tumor-bearing and disease-
free breasts. Our findings have important implications as
they suggest that proteomic screening techniques using
ICAT and NAF may be used to find markers for diagnosis
of breast cancer.
Methods
Patients and sample collection
NAF samples were obtained from 18 women with stage I
or II unilateral invasive breast carcinoma who presented
to The University of Texas M. D. Anderson Cancer Center's
Nellie B. Connally Breast Center. NAF was also collected
from 4 healthy volunteers not related to the patients. Indi-
viduals were eligible to participate if they had not previ-
ously undergone subareolar surgery, which might have
disrupted the terminal ductal system. All participants gave
written informed consent to undergo bilateral nipple aspi-
ration. The study protocol was approved by M. D. Ander-
son Cancer Center's institutional review board.
Before aspiration was attempted, the nipple was initially
cleansed with a small amount of Omniprep paste (D.O.
Weaver and Co., Aurora, CO) to remove any keratin plugs
and then wiped with an alcohol pad. A small amount of
lotion was placed on the breast, and the breast was gently
massaged from the chest wall toward the nipple for 1
minute. Ductal fluid was collected as previously described
by Sartorius et al. [29]. In brief, nipple aspiration was
accomplished using a handheld suction cup (Product
Health, Inc., Menlo Park, CA) similar to the nonpowered
breast pumps commonly used to express milk from lactat-
ing women. With the suction cup over the nipple, the
plunger of the syringe was withdrawn to the 5- to 10-mL
level until ductal fluid was visualized. The fluid droplets
were collected into a 10-µl graduated micropipette
(Drummond Scientific Co., Broomall, PA). In the case of
women with breast cancer, NAF was collected separately
from the tumor-bearing and disease-free breasts. The vol-BMC Cancer 2006, 6:68 http://www.biomedcentral.com/1471-2407/6/68
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umes of NAF were recorded for each patient and each
breast.
Immediately after collection, the NAF samples were rinsed
into centrifuge tubes containing sterile phosphate-buff-
ered saline supplemented with the protease inhibitors 4-
(2-aminoethyl)-benzenesulfonylfluoride HCl (0.2 mM),
leupeptin (50 µg/mL), aprotinin (2 µg/mL), and dithioth-
reitol (0.5 mM). The samples were then centrifuged at
1500 RPM for 10 minutes, and the supernatants were col-
lected and suspended in a 500 µl PBS buffer with the pre-
viously mentioned protease inhibitors.
ICAT analysis
ICAT analysis was performed using a Cleavable ICAT Rea-
gent Kit (Applied Biosystems, Foster City, CA) according
to the manufacturer's guidelines with some modifications
(Figure 1) [30]. For ICAT analysis, the NAF protein sam-
ples from the tumor-bearing breasts and disease-free
breasts of patients with early-stage breast cancer were
respectively pooled in a normalized fashion. One hun-
dred micrograms of each NAF protein pool was separately
reduced in 80 µL of denaturing buffer at 37°C for 2 hours
with 5 mM TCEP and alkylated at 37°C for 2 hours in the
dark with ICAT-heavy (NAF from tumor-bearing breasts)
and ICAT-light (NAF from disease-free breasts) reagent.
After alkylation, ICAT-heavy and ICAT-light reactions
were mixed together and concentrated by centrifugal
evaporation, SDS-PAGE loading buffer was added, and
the sample was separated by SDS-PAGE. The gel was cut
into 14 slices and subjected to in-gel trypsin digestion at
37°C for 20 hours. After extraction, the ICAT-labeled pep-
tides were purified using the ICAT Avidin Buffer Pack and
Avidin Affinity Cartridge kit (Foster City, CA) according to
the manufacturer's guidelines. Briefly, the peptide mixture
was dried by vacuum centrifugation and resolubilized in
the loading buffer of the kit. The peptide mixture was
loaded in the Avidin Affinity Cartridge and washed twice
with two kinds of wash buffer (first wash in 2× PBS fol-
lowed by a second wash in 50 mM NH4HCO3 in 20%
MeOH) to reduce the salt concentration and remove non-
specifically bound peptides. The ICAT-labeled peptides
were then eluted with the elution buffer and dried by vac-
uum centrifugation. The dried peptides were cleaved from
the biotin portion of the ICAT reagent with the cleaving
reagents at 37°C for 2 hours. The ICAT-labeled peptides
were then dried by vacuum centrifugation and resolubi-
lized in 2% formic acid for liquid chromatography and
MS.
Liquid chromatography and mass spectrometry
Liquid chromatography and MS were performed using an
LCPackings nano-LC system consisting of an Ultimate
pump, Famos autosampler, and Switchos column-switch-
ing device for on-line desalting (Dionex Corp., Sunnyvale,
CA). The Switchos was fitted with a C18 reversed phase
column (Pepmap C18, 300 µmIDx1 mm,) and a C18
reversed phase nanocolumn (Pepmap C18, 75 µmIDx10
mm). Reversed phase solvents were 0.005% heptafluor-
obutyric acid in either water and 2% acetonitrile or 80%
acetonitrile. Gradient elutions were performed over 90
minutes from about 5% acetonitrile to about 40% fol-
lowed by flushing with 72% acetonitrile and reequilibra-
tion for the next injection. Spectra were acquired on a
QqTOF quadrupole/time-of-flight mass spectrometer
(Qstar Pulsar-I, Applied Biosystems/MDS Sciex, Foster
City, CA). Qstar was externally calibrated, using the dou-
bly and triply charged peaks of the peptide neurotensin.
One survey MS scan was followed by two MS/MS scans on
the two most intense ions from the MS spectrum, omit-
ting previously selected targets.
Database searches
The acquired MS/MS spectra were automatically com-
pared against the National Center for Biotechnology
Information (NCBI) database using the ProICAT program
(Applied Biosystems/MDS Sciex) allowing 1 missed cleav-
age (trypsin) and 0.3 and 0.5 d windows for MS/MS and
MS resp. Modifications allowed were fairly typical: ICAT
on Cys, Met oxidation. The same program was also used
to calculate ICAT ratios. The ICAT experiment by design
produced fewer peptides, but the requirement of contain-
ing Cys increases the confidence of the one peptide hits
when manually curated (as these were). We extracted
tables of high-confidence (99%) matched peptides with
their ratios and used them for further calculations. The
Schema of ICAT analysis performed using a Cleavable ICAT  Reagent Kit (Applied Biosystems, Foster City, CA) according  to the manufacturer's guidelines, with some modifications Figure 1
Schema of ICAT analysis performed using a Cleavable ICAT 
Reagent Kit (Applied Biosystems, Foster City, CA) according 
to the manufacturer's guidelines, with some modifications. 
Avidin Affinity refers to the Avidin Affinity Cartridge kit 
(Applied Biosystems, Foster City, CA)BMC Cancer 2006, 6:68 http://www.biomedcentral.com/1471-2407/6/68
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quality of peptide matches of interest was checked manu-
ally.
Western blot analysis
Protein samples (40 µg) were separated on a 10% SDS-
PAGE gel and transferred (170 V for 45 minutes) to nitro-
cellulose filters (pure nitrocellulose; pore size, 0.45 µm;
Bio-Rad, CA). Blots were blocked overnight at 4°C in 5%
(wt/vol) skim milk-TTBS (0.1% Tween 20-Tris-buffered
saline). The next morning the membranes were incubated
for 1 hour in 5% skim milk in PBS with polyclonal anti-
vitamin D-binding protein (Biodesign International,
Saco, ME) diluted 1:1000. Membranes were then incu-
bated with goat anti-rabbit secondary antibody (Santa
Cruz, CA) for 1 hour at 4°C. The bound antibody was vis-
ualized using the ECL-Plus Detection kit (Amersham
Pharmacia Biotech, Piscataway, NJ) and the bands were
analyzed by video imaging and densitometry.
Statistical analyses
Densitometry measurements were analyzed and statistical
significance was determined using independent Student's
t-test. A standard cut-off of 15–20% change is commonly
utilized to denote differential expression. In the current
experiments, a peptide ratio of 1.56 correlated with one
standard deviation above the median ratio.
Results
The median age for the 18 patients with stage I or II uni-
lateral invasive breast carcinoma was 48 years. The major-
ity of the patients (73%) were premenopausal. The
median age of the volunteers was 55 years. All 4 healthy
volunteers were postmenopausal.
ICAT analysis of NAF
NAF from the tumor-bearing breasts versus disease-free
breasts of 10 patients with unilateral early stage breast
cancer was assessed by ICAT analysis. Using the ProICAT
bioinformatics program, 353 peptides were identified
with a high level of confidence (> 99%) on the basis of
matching of tandem mass spectra of peptides to peptide
sequences in the NCBI database. Approximately equal
numbers of peptides were up- versus down-regulated (Fig-
ure 2). Following manual review of all peptide match
spectra and exclusion of redundant matches, 39 proteins
were identified that had sufficient quality to justify assign-
ment (Table 1). Twenty proteins (51%) were identified
based on two or more peptide matches; 19 proteins
(49%) were identified based on a single peptide match.
As previously noted, peptides from tumor-bearing breasts
had a heavy tag, and peptides from disease-free breasts
had a light tag. Of the 39 proteins, 19 had an ICAT ratio
Using the ProICAT bioinformatics program, 353 peptides were identified Figure 2
Using the ProICAT bioinformatics program, 353 peptides were identified. Approximately equal numbers of proteins were up- 
versus down-regulated.BMC Cancer 2006, 6:68 http://www.biomedcentral.com/1471-2407/6/68
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of Heavy:Light (H:L) > 1.0, 16 proteins had an ICAT ratio
of H:L < 1.0, and 1 protein had an ICAT ratio of H:L = 1.0.
In three cases, a peptide signal could only be convincingly
detected in one, not both states (diseased versus not), so
no ratio could be calculated. Proteins that were differen-
tially expressed between the NAF from tumor-bearing
breasts and the NAF from disease-free breasts included,
among others, alpha2HS-glycoprotein (H:L ratio 0.63),
lipophilin B (H:L ratio 1.42), beta-globin (H:L ratio 1.98),
hemopexin (H:L ratio 1.73), and vitamin D-binding pro-
tein precursor (H:L ratio 1.82) (Table 1). For the one-pep-
tide hit of interest, Vitamin-D binding protein, a second
peptide, not containing Cys was identified using Mascot
(data not shown).
The finding that ICAT identified vitamin D-binding pro-
tein as being overexpressed in NAF from the tumor-bear-
ing breasts of women with early-stage breast cancer was
particularly interesting (Figures 3 and 4). Previous studies
[31-34] have suggested that the vitamin D receptor may be
overexpressed in breast tumors. We therefore sought to
examine further the expression of vitamin D-binding pro-
tein in a separate, independent set of NAF specimens to
validate the ICAT vitamin D findings.
Western blot analysis
To assess the correspondence of the ICAT vitamin D-bind-
ing protein data with an independent assay of protein
abundance, we performed Western blot analysis on NAF
obtained from a separate cohort of 12 women (4 healthy
volunteers and 8 women with early-stage breast cancer).
On western blot analysis, vitamin D-binding protein
expression in the pooled samples of NAF specimens from
women with early-stage breast cancer was twice that in the
NAF specimens from healthy volunteers (P = 0.04; stand-
ard error = 9703.7) (Figure 5). Interestingly, the relative
difference in expression was similar to the abundance
ratio derived from ICAT analysis (1.82). Although the
data derived from ICAT and pooled western analyses were
similar, western blot analysis of individual NAF speci-
mens showed variation in vitamin D-binding protein
expression among both healthy volunteers and women
with early-stage breast cancer (Figure 5). Menopausal sta-
tus did not affect expression of vitamin D-binding protein
expression in NAF from women with early-stage breast
cancer (P = 0.57; standard error = 14425.3).
Discussion
To our knowledge, the current study is the first proteomic
analysis of women with breast cancer using ICAT tandem
MS and NAF. NAF was chosen as a substrate to evaluate
biomarkers of breast disease because nipple aspiration is
Quantification of vitamin D-binding protein through the ICAT-labeled parent ion signals of the peptide VC*SQYAAYGEK Figure 3
Quantification of vitamin D-binding protein through the ICAT-labeled parent ion signals of the peptide VC*SQYAAYGEK.BMC Cancer 2006, 6:68 http://www.biomedcentral.com/1471-2407/6/68
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simple, quick, reliable, and reproducible [13-15,35,36].
In addition, nipple aspiration is completely noninvasive
and requires a device with only minimal cost. Nipple aspi-
ration provides concentrated secreted proteins not diluted
with the irrigation fluid that is required to perform proce-
dures such as ductoscopy or ductal lavage. Because of this,
NAF is a rich source of proteins [37], thereby making it a
good potential candidate as a source of biomarkers for
early diagnosis of breast cancer [35,37-40].
In the current study, ICAT identified 39 proteins that were
differentially expressed in tumor-bearing versus disease-
free breasts. Among the proteins identified, alpha2HS-
glycoprotein was underexpressed, while lipophilin B,
beta-globin, hemopexin, and vitamin D-binding protein
precursor were overexpressed. A number of other proteins
were identified, however these identifications had lower
ProICAT scores. Despite being confirmed with manual
curation, one may need to use Mascot or other secondary
filters to eliminate the chance of false positive identifica-
tion.
Alpha2HS-glycoprotein is important in blocking trans-
forming growth factor-beta1 signal transduction, which is
associated with tumor progression and resistance to
chemotherapy in established cancers [41,42]. Alpha2HS-
glycoprotein has been observed to be depleted in certain
tumors compared with normal tissue [42], consistent with
the decreased ICAT ratio reported here.
Overexpression of lipophilin B, beta-globin, and hemo-
pexin has also been confirmed in tumor-bearing tissues
using non-ICAT techniques. Specifically, lipophilin B
mRNA is overexpressed in 70% of breast tumors, and
serum antibodies to lipophilin B have been detected in
breast cancer patients [43-45]. Similarly, beta-globin has
been found to be overexpressed in a number of different
cancers compared with normal tissue [46-48]. Hemo-
pexin, a protein involved in matrix metalloproteinase
(MMPs) activation, has been linked to invasion and
metastasis in many cancer model systems, including
human breast cancer [49]. MMP activation requires an
intact hemopexin domain, and overexpression of hemo-
pexin may increase MMP activity, degradation of extracel-
lular matrix, and tumor cell migration [50,51].
Our finding that vitamin D-binding protein precursor was
overexpressed in the tumor-bearing breasts of women
with breast cancer also agrees with previous findings.
Receptors for 1,25-dihydroxyvitamin D have been shown
to exist in cultured breast cancer cells and in primary
breast cancers [32-34,52]. In fact, the vitamin D-receptor
Identification of the peptide VC*SQYAAYGEK from vitamin D-binding protein by MS/MS Figure 4
Identification of the peptide VC*SQYAAYGEK from vitamin D-binding protein by MS/MS.BMC Cancer 2006, 6:68 http://www.biomedcentral.com/1471-2407/6/68
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has been reported to be present in 80% of breast cancers
[32] and to be expressed at significantly higher concentra-
tions in breast cancers than in normal breast tissue [31].
ICAT technology has been successfully used to study pro-
tein expression in yeast [16,19], plant [53], and mamma-
lian hematopoietic [25,54] and liver cells [55]. A review of
the available literature reveals, however, that ICAT tech-
nology has not been employed in the clinical investiga-
tion of breast cancer. To date, only one study [56] has
utilized stable isotope proteomic analysis to investigate
ductal carcinoma of the breast. Zang et al. [56] compared
protein expression between 10,000 cells each of microdis-
sected normal ductal epithelium and metastatic ducal car-
cinoma using MS/MS in combination with 16O/18O
isotopic labeling introduced enzymatically. A total of 76
proteins were identified, and some of the proteins – such
as mitochondrial isocitrate dehydrogenase, actin, and 14-
3-3 protein xi/delta – were found to be significantly upreg-
ulated in breast tumor cells [56]. Although similar to
ICAT, the stable isotope technique used in these experi-
ments did not employ an affinity component to enhance
the separation of the labeled peptides.
ICAT technology is still in the early phase of development
and should be regarded as a screening step to identify
potentially interesting protein changes, which need to be
independently confirmed by immunoblotting before they
can be considered confirmed [25]. In the current study, we
performed western blot analysis on independent NAF
samples to confirm the overexpression of vitamin D-bind-
ing protein that had been noted with ICAT. Due to limited
sample material, immunoblotting could not be per-
formed on the other proteins identified by ICAT. Vitamin
D-binding protein was chosen because of its known asso-
ciation with breast cancer and because it had a high ICAT
ratio (1.82), indicating significantly different expression
in the tumor-bearing breast versus disease-free breasts.
Western blot analysis confirmed that, in general, vitamin
D-binding protein was significantly overexpressed in NAF
Western blot analysis of independent NAF sample set Figure 5
Western blot analysis of independent NAF sample set. The relative difference in vitamin D-binding protein expression in the 
pooled samples of NAF from healthy volunteers versus NAF from women with early-stage breast cancer was two-fold (P = 
0.04; standard error = 9703.7 (solid bars). Individual NAF specimens showed variation in vitamin D-binding protein expression 
among both healthy volunteers and women with early-stage breast cancer (dotted bars). Menopausal status did not affect 
expression of vitamin D-binding protein in NAF.BMC Cancer 2006, 6:68 http://www.biomedcentral.com/1471-2407/6/68
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obtained from women with breast cancer, although there
was variation in expression among patients. Comparison
of abundance ratios measured by ICAT and by Western
blotting of the pooled specimens showed similar values
(i.e., a two-fold increase in vitamin D-binding protein in
the NAF from the tumor-bearing versus disease-free
breasts). Previous reports have confirmed that the ICAT
method is highly accurate for the quantification of pro-
teins. The ICAT method has accurately predicted the rela-
tive quantification of proteins at known concentrations in
mixtures [16,19,57,58]. Comparison of abundance ratios
obtained by ICAT and by Western blot analysis has also
consistently shown similar values [59]. In aggregate, these
data strongly suggest that the ICAT method can be used to
accurately measure the changes in abundance of differen-
tially expressed proteins.
Reports in the literature indicate that ICAT technology can
identify over 100 proteins per sample [9]. The relatively
small number of proteins identified in the current study
was most likely related to the preponderance of a few
highly abundant, but non-specific, proteins in NAF. Simi-
lar to serum and plasma, in which about 75% of the total
protein is comprised of albumin or immunoglobulins,
NAF has high levels of albumin, lactotransferrin, immu-
noglobulins, and apolipoprotein D. In the future, we
intend to remove these proteins prior to ICAT analysis to
facilitate the MS identification of other, potentially more
relevant proteins. Newer stable-isotope technology such
as the iTRAQ system (Applied Biosystems), which allows
for the direct comparison of up to four samples in a single
experiment rather than the two samples possible with
ICAT, may be informative. Use of this strategy would
allow the direct inclusion of two additional clinically rel-
evant samples – such as NAF from women with ductal car-
cinoma in situ and NAF from women with fibrocystic
disease.
Conclusion
Proteomics has the potential to be a powerful tool in iden-
tifying molecules to assist in the diagnosis and treatment
of breast cancer. In fact, Somiari et al. [9] and others [7]
have argued that breast cancer prognostication and man-
agement will be significantly improved only by the use of
multiple biomarkers, which most likely will be identified
by proteomic analysis of breast carcinoma. Comprehen-
sive analysis of proteomic profiles derived from biologic
tissues and fluids remains, however, a formidable task.
Complex protein mixtures must be resolved into individ-
ual proteins or manageable groups of proteins, quanti-
fied, and then identified. ICAT technology enables not
only qualitative but also quantitative analysis of normal
and diseased specimens, making identification of cancer-
specific protein markers possible. The quantitative pro-
teomic strategy of ICAT and NAF utilized in the current
study is an example of a novel approach to discovering
biomarkers in women with breast cancer.
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